Aprepitant adverse effects

PROTEASE INHIBITORS ANTI EMETICS -APREPITANT t adverse effects of aprepitant with nelfinavir and ritonavir (with or without lopinavir) Inhibition of CYP3A4-mediated metabolism of aprepitant Use with caution clinical significance unclear monitor closely... 

Although the effect of these increases has not been assessed, such marked increases in levels could increase adverse effects. The manufacturers recommend caution when aprepitant is given with ketoconazole and other drugs that are strong inhibitors of CYP3A4. They specifically name ritonavir, clarithromycin, telithromycin, itraconazole, ne-fazodone, troleandomycin, and nelfinavir. For the effect of diltiazem (a moderate CYP3A4 inhibitor), see Calcium-channel blockers + Aprepi-tanf, p. 861. Other inhibitors of CYP3A4 are listed in Table 1.4 , (p.6). 

The results of various clinical trials indicated that the incidence of adverse events was similar in the aprepitant group compared with the group which received only standard regimen of ondansetron and dexamethasone. The most commonly observed side effects with aprepitant treatment were asthenia, hiccups, diarrhea, gastritis, elevation in fiver function tests, and dizziness. There are also reports of thrombocytopenia and dehydration. 

---

See also in sourсe #XX -- [ ]

---